FDG-PET imaging has become an accepted, reimburseable approach for diagnosing Alzheimer's and other neurodegenerative diseases.
CONTEXT: FDG-PET imaging has become an accepted, reimburseable approach for diagnosing Alzheimer's and other neurodegenerative diseases. No clinically practical method has been proven to predict rate of cognitive degeneration of individuals, however. Dr. Daniel Silverman, an associate professor of molecular medicine and pharmacology at the University of California, Los Angeles, is developing a way to quantify FDG-PET data to predict the rate of cognitive decline.
RESULTS: Silverman and Dr. Gary Small, director of the UCLA Center on Aging, studied 25 subjects using formal neuropsychologic tests and standard clinical brain scans at baseline and two years later. Brain metabolism for each subject was automatically analyzed, using a standardized region of interest (sROI) approach that examines 240 regions and groups them into 42 regional clusters. As the most common types of neurodegenerative processes involving progressively diminished language and memory are associated with posterior-predominant hypometabolism, an index was constructed to capture the posterior/anterior gradient reflected by loss of metabolism in some posterior regional clusters.
FDG-PET predicted the rate of cognitive decline in some subgroups of patients within 20% of the actual rate of change.
IMAGE: Standardized ROI approach automatically quantifies loss of metabolism in some posterior regional clusters (planes 22, 24, and 32) relative to metabolism of some better preserved regional clusters in prefrontal cortex (plane 20) in individual subjects.
IMPLICATIONS: This study demonstrated the feasibility of using an automated analysis of FDG-PET scans in a clinical setting to predict rates of cognitive decline.
"It's a promising start," said Dr. Silverman. "But research needs to be done with much larger groups of subjects."
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Could Ultrafast MRI Enhance Detection of Malignant Foci for Breast Cancer?
April 10th 2025In a new study involving over 120 women, nearly two-thirds of whom had a family history of breast cancer, ultrafast MRI findings revealed a 5 percent increase in malignancy risk for each second increase in the difference between lesion and background parenchymal enhancement (BPE) time to enhancement (TTE).
AMA Approves Category III CPT Codes for AI-Enabled Perivascular Fat Analysis from CT Scans
April 9th 2025Going into effect in 2026, the new CPT codes may facilitate increased adoption of the CaRi-Heart software for detecting coronary inflammation from computed tomography scans pending FDA clearance of the technology.